ClinicalTrials.gg
RecruitingNCT05920343PREVENT-GUUpdated Nov 12, 2026

VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy

A Phase 2/3 interventional study of Rivaroxaban 10 MG and Placebo control in Venous Thromboembolism and Urologic Cancer, sponsored by Ottawa Hospital Research Institute. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Ottawa Hospital Research Institute · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 12, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies testing rivaroxaban in Venous Thromboembolism — 18 open to participants now, 18 under way, 6 of them phase 3. Rivaroxaban · Venous Thromboembolism.

Planned enrollment
44th of 61
120 · median 272
Started
2024
with 6 others
Phase 2/3
3 of 61
1 open now
Primary completion
2028-06
later than 16 of 17 live
Registered
48th of 61
by date
Lead sponsor
4 of 61
Ottawa Hospital Research Institute

Among the 61 studies testing rivaroxaban in Venous Thromboembolism, this one is the 44th largest by planned enrollment, is one of 7 that started in 2024, is one of 3 in phase 2/3, reaches primary completion later than 16 of the 17 other live ones, and was the 48th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

18 of the 61 studies testing rivaroxaban in Venous Thromboembolism are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing rivaroxaban in Venous Thromboembolism, or all of them as a file.
02

Study summary

Patients with genitourinary cancers (ex: bladder, testicular, kidney) are at high risk of developing blood clots if they receive systemic therapy (ex: chemotherapy, immunotherapy). Blood clots cause pain, may require hospitalization and invasive testing, and in some cases cause death. In fact, blood clots are one of the leading causes of death in patients with cancer. Furthermore, patients who develop a blood clot require medication to thin the blood for a prolonged (sometimes indefinite) period of time, and this can disrupt other important cancer treatments. Studies have shown that using low dose blood thinners to prevent blood clots during systemic therapy is effective in some patients with cancer. However very few patients in these studies had genitourinary cancers, therefore physicians in Canada are not sure if recommending blood thinners to patients with genitourinary cancers is useful or safe. Safety is a primary concern because blood thinners may cause bleeding, and patients with genitourinary cancers may have higher risk of bleeding than patients with other types of cancer. The investigators hypothesize that blood thinners are effective and safe for reducing blood clots in patients with genitourinary cancers. The objective of this study is to determine if a large clinical trial testing the effectiveness and safety of low dose blood thinners for preventing blood clots in patients with genitourinary cancers receiving systemic therapy is feasible.

Read the detailed description

Background and Importance: Patients with cancer receiving systemic therapy are at high risk of venous thromboembolism (VTE). Thromboprophylaxis with antiocoagulants reduces VTEs during chemotherapy by 60%. Despite this, thromboprophylaxis is not routinely used in Canada for patients with genitourinary (GU) malignancies (bladder, testis, kidney). Reasons prophylaxis is not used are that very few GU patients were included in landmark trials evaluating DOACs, and because GU patients may be at higher risk of bleeding compared to non-GU cancer patients. The omission of GU patients from prior trials has created an important gap in knowledge because these patients have among the highest risk of VTE of all cancer patients. Prior studies have reported VTE rates during chemotherapy for bladder and testis cancer in the range of 10-15%, well above thresholds at which guidelines usually recommend thromboprophylaxis.

Hypotheses: The investigators hypothesize that thromboprophylaxis with a direct oral anticoagulant (DOAC) during systemic therapy for GU malignancies will reduce the risk of VTE with acceptable risk of major bleeding. Secondly, the investigators hypothesize that a randomized trial of thromboprophylaxis versus placebo in GU patients is feasible and needed to change care in Canada.

Research goals: The goal of this pilot study is to determine if a randomized control trial of thromboprophylaxis with rivaroxaban versus placebo in GU patients receiving systemic therapy is feasible.

Methods: This internal pilot feasibility study will randomize patients with GU malignancies receiving systemic therapy (patients) to rivaroxaban 10mg daily (intervention) versus placebo (control). The primary outcome of this internal pilot study will be feasibility of patient accrual. Feasibility will be reported as the average number of patients enrolled per month. Secondary outcomes will be time to trial initiation, number of patients enrolled per site, and proportion of patients who complete the intervention. If feasibility is confirmed, patients enrolled in the pilot will be included in the full trial using a vanguard design.

The primary outcome(s) of the full trial will be VTE (efficacy outcome) and major bleeding (safety outcome) during the intervention. Patient reported outcomes including quality of life will also be recorded.

Expected outcomes: While thromboprophylaxis is effective in cancer patients, medical guidelines only recommend prophylaxis for some patients due to limited evidence in disease-specific subgroups. Importantly, safety concerns in GU patients are a particular concern necessitating further study of this population. The investigators expect the results of this internal pilot study to prove feasibility of a full trial. The full trial will determine the net benefits/harms of prophylaxis in GU patients and change practice worldwide, regardless of the results.

03

Conditions studied

  • Venous Thromboembolism
  • Urologic Cancer

Keywords

  • Genitourinary Cancer
  • Venous Thromboembolism
  • Systemic Therapy
  • Thromboprophylaxis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are starting systemic therapy for active GU cancer (bladder, testis, ureter/renal pelvis, kidney, urethral, penile) except for prostate cancer.
  • Age ≥ 18
  • Eligible systemic therapies include chemotherapy, targeted therapies (tyrosine kinase inhibitors and antiangiogenic therapy), and immunotherapies.
  • Patients must be initiating systemic therapy with a minimum planned treatment duration of 8 weeks.

Exclusion criteria

Exclusion Criteria:

  • Anticoagulation (prophylactic or therapeutic dosing) required for another indication for entire duration of study
  • Known allergies to rivaroxaban
  • Concomitant use of dual antiplatelet therapy (two antiplatelet medications oncomitantly)
  • Ongoing bleeding that may be exacerbated by rivaroxaban.
  • Concomitant use of strong inducers or inhibitors of or glycoprotein-P (known interaction with rivaroxaban).
  • Severe renal insufficiency ( \<30 mL/min (defined by Cockcroft-Gault))
  • Severe liver disease (e.g. acute clinical hepatitis, chronic active hepatitis, cirrhosis)
  • Thrombocytopenia \< 50 x 109/L
  • under 6 months.
  • Pregnancy (if child bearing age under 50 and sexually active, documentation of use of effective or negative B- HCG is required)
  • Patient is breastfeeding or lactating
  • History of condition at increased bleeding risk including, but not limited to:

cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, spontaneous or acquired impairment of hemostasis in the previous 4 weeks.

  • Chronic hemorrhagic disorder
  • Inability to adhere to protocol or obtain consent.
  • Patients may be excluded from the study for other reasons, at the investigator's discretion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Rivaroxaban

    Participants receiving study drug (Rivaroxaban)

    Drug: Rivaroxaban 10 MG

  • Placebo comparator
    Control

    Participants receiving matched placebo

    Other: Placebo control

Interventions

  • DrugRivaroxabanStudies of RivaroxabanRivaroxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).

    Also known as: Xarelto

  • OtherPlacebo control

    Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug

06

What researchers measure

Primary outcomes

  1. Feasibility of enrollment, assesed by the number of patients accrued per month

    The primary outcome of this Pilot Trial is feasibility of enrollment. Feasibility will be measured by the average number of patients accrued per month.

    Time frame: Enrollment

Secondary outcomes

  1. Adherence to the study intervention, assessed as the proportion of patients taking the study medication >80% of days taken during the study period,

    This outcome will measure patient adherence to the study intervention (defined as \>80% of medication taken during the study intervention period). This will be assessed using pill counts during study follow-ups.

    Time frame: During 180 days of study intervention

  2. Recruitment rate

    Number of participants recruited per month at each study site

    Time frame: Enrollment

  3. VTE incidence

    VTE will be recorded and adjudicated similarly to the full trial. Outcomes will be examined in aggregate to ascertain an estimate of baseline risk for patients in the trial. VTE outcomes will NOT be examined or reported by allocation group in the Pilot so all patients can be included in Full Trial analyses (internal pilot design).

    Time frame: During 180 days of study intervention

  4. Bleeding incidence

    Bleeding outcomes (major and minor) will be recorded and adjudicated similarly to the full trial. Outcomes will be examined in aggregate to ascertain an estimate of baseline risk for patients in the trial. Bleeding outcomes will NOT be examined or reported by allocation group in the Pilot so all patients can be included in Full Trial analyses (internal pilot design).

    Time frame: During 180 days of study intervention

Other outcomes

  1. VTE-related death

    VTE-related death will be collected during the pilot but will not be analyzed until the full trial. VTE-related death will assess the frequency of deaths among participants directly related to a VTE event.

    Time frame: During 180 days of study intervention

  2. Overall survival

    Overall survival will be collected during the pilot but will not be analyzed until the full trial. Overall survival will assess the frequency with which participants die by any cause during the intervention.

    Time frame: During 180 days of study intervention

  3. Health-related Quality of Life assessed using the EQ-5D-5L Score

    Health-related Quality of Life will be collected during the pilot but will not be analyzed until the full trial. Health-related Quality of Life will be assessed using the EQ-5D-5L questionnaire. EQ-5D-5L contains two scores: The VAS ranges from 0-100 and represents a patient's sense of their overall health. Higher VAS scores represent a better outcome. The second measure is the EQ-5D-5L index which ranges from 0-1 (scores are reported with three decimal points) and shows quality of life along 5 dimensions which are weighted based on regional values in the final index score. Higher index scores represent a better outcome

    Time frame: During 180 days of study intervention

  4. Incremental cost-effectiveness ratio

    Incremental cost-effectiveness ratio will be collected during the pilot but will not be analyzed until the full trial. Incremental cost-effectiveness ratio will take the form of a cost utility analysis with outcome expressed as incremental cost per quality adjusted life year (QALY) gained.

    Time frame: During 180 days of study intervention

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan to share individual participant data with other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2024 (actual). Primary completion is estimated for Jun 2028, 43 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Oct 2026 → Jun 2028 and completion Oct 2026 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2023
First posted
Jun 27, 2023
StartActual
Nov 4, 2024
Primary completionEst.
Jun 2028was Oct 2026
CompletionEst.
Jun 2028was Oct 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Canada)
  • Juravinski Cancer Centre · Hamilton, Canada
  • London Health Sciences Centre · London, Canada
Nov 12, 2026
Primary completion
Oct 2026→Jun 2028
Nov 12, 2026
Study completion
Oct 2026→Jun 2028
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    2 sites added
    Show 2 added (2 Canada)
    • Juravinski Cancer Centre · Hamilton, Canada
    • London Health Sciences Centre · London, Canada
    Primary completion Oct 2026→Jun 2028
    Study completion Oct 2026→Jun 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05920343
Collaborators
Canadian Institutes of Health Research (CIHR), Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, Kidney Cancer Research Network of Canada
Responsible party
Sponsor
First posted
Jun 27, 2023
Start date
Nov 4, 2024
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Luke T Lavallee, MDCM MSc FRCSC
Contact
lulavallee@toh.ca
613-737-8899 ext. 71393
David J Yachnin, MSc
Contact
dyachnin@toh.ca
613-798-5555 ext. 74639
Luke T Lavallee, MDCM MSc FRCSC
principal investigator · Ottawa Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion